Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

IgG4 antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (4) Antibody-Drug Conjugates (ADCs) (1) Human leukocyte immunoglobulin (Ig)-like receptors (LILR) (1) VISTA (1) Akt (1) Amyloid-β (1) ANGPTL (1) Apelin Receptor (APJ) (1) Apolipoprotein (1) Apoptosis (7) Aquaporin (1) ATGL (1) c-Fms (1) c-Met/HGFR (3) c-Myc (1) C-type Lectin-like Receptors (CTLRs) (2) Cadherin (2) Caspase (1) CCR (4) CD19 (1) CD20 (1) CD22 (2) CD28 (7) CD3 (9) CD38 (2) CD47 (11) CD73 (1) CGRP Receptor (1) Claudin (1) Complement System (5) CTLA-4 (1) CXCR (5) Dan family (1) EGFR (1) ERK (2) Factor VIII (1) Factor Xa (4) Fc Receptor (FcR) (2) Ferroportin (1) GCGR (2) GDNF Receptor (2) Hepcidin (1) HIV (4) IFNAR (4) IGF-1R (1) Integrin (7) Interleukin Related (32) LAG-3 (8) LILRB (3) MHC (1) MMP (2) Mucin (2) MyD88 (1) Myosin (1) NAMPT (1) Natriuretic Peptide Receptor (NPR) (2) Neuropeptide Y Receptor (1) NF-κB (2) NOD-like Receptor (NLR) (1) NTPDase (1) Orexin Receptor (OX Receptor) (2) P-selectin (1) p38 MAPK (1) PACAP Receptor (1) PAI-1 (1) PCSK9 (2) PD-1/PD-L1 (27) PDGFR (1) Prion Protein (1) PSMA (2) RANKL/RANK (1) SARS-CoV (2) Scavenger Receptor Class B type I (SR-BI） (1) Ser/Thr Protease (3) Small Interfering RNA (siRNA) (1) STAT (1) TAM Receptor (2) Tau Protein (6) TGF-beta/Smad (4) TGF-β Receptor (3) Thrombin (2) Tim3 (2) TNF Receptor (18) Toll-like Receptor (TLR) (4) Transmembrane Glycoprotein (18) Trk Receptor (1) VEGFR (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (97) Cardiovascular Disease (18) Endocrinology (1) Infection (7) Inflammation/Immunology (137) Metabolic Disease (5) Neurological Disease (14)

By Targets:

ADC Antibody (4)

Antibody-Drug Conjugates (ADCs) (1)

Human leukocyte immunoglobulin (Ig)-like receptors (LILR) (1)

VISTA (1)

Akt (1)

Amyloid-β (1)

ANGPTL (1)

Apelin Receptor (APJ) (1)

Apolipoprotein (1)

Apoptosis (7)

Aquaporin (1)

ATGL (1)

c-Fms (1)

c-Met/HGFR (3)

c-Myc (1)

C-type Lectin-like Receptors (CTLRs) (2)

Cadherin (2)

Caspase (1)

CCR (4)

CD19 (1)

CD20 (1)

CD22 (2)

CD28 (7)

CD3 (9)

CD38 (2)

CD47 (11)

CD73 (1)

CGRP Receptor (1)

Claudin (1)

Complement System (5)

CTLA-4 (1)

CXCR (5)

Dan family (1)

EGFR (1)

ERK (2)

Factor VIII (1)

Factor Xa (4)

Fc Receptor (FcR) (2)

Ferroportin (1)

GCGR (2)

GDNF Receptor (2)

Hepcidin (1)

HIV (4)

IFNAR (4)

IGF-1R (1)

Integrin (7)

Interleukin Related (32)

LAG-3 (8)

LILRB (3)

MHC (1)

MMP (2)

Mucin (2)

MyD88 (1)

Myosin (1)

NAMPT (1)

Natriuretic Peptide Receptor (NPR) (2)

Neuropeptide Y Receptor (1)

NF-κB (2)

NOD-like Receptor (NLR) (1)

NTPDase (1)

Orexin Receptor (OX Receptor) (2)

P-selectin (1)

p38 MAPK (1)

PACAP Receptor (1)

PAI-1 (1)

PCSK9 (2)

PD-1/PD-L1 (27)

PDGFR (1)

Prion Protein (1)

PSMA (2)

RANKL/RANK (1)

SARS-CoV (2)

Scavenger Receptor Class B type I (SR-BI） (1)

Ser/Thr Protease (3)

Small Interfering RNA (siRNA) (1)

STAT (1)

TAM Receptor (2)

Tau Protein (6)

TGF-beta/Smad (4)

TGF-β Receptor (3)

Thrombin (2)

Tim3 (2)

TNF Receptor (18)

Toll-like Receptor (TLR) (4)

Transmembrane Glycoprotein (18)

Trk Receptor (1)

VEGFR (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (97)

Cardiovascular Disease (18)

Endocrinology (1)

Infection (7)

Inflammation/Immunology (137)

Metabolic Disease (5)

Neurological Disease (14)

234

Inhibitors & Agonists

258

Inhibitory Antibodies

Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) Human leukocyte immunoglobulin (Ig)-like receptors (LILR) VISTA ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9902

Pembrolizumab Maximum Cited Publications 30 Publications Verification MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P9903

Nivolumab 20+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Infection Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99055

Urelumab	TNF Receptor	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99100

Visugromab 2 Publications Verification CTL-002	TGF-beta/Smad PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99021

Galcanezumab 1 Publications Verification LY 2951742	CGRP Receptor	Neurological Disease
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .

HY-P99632

Garetosmab 1 Publications Verification REGN 2477	TGF-β Receptor	Inflammation/Immunology
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .

HY-P99971

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99706

Ligufalimab 1 Publications Verification AK 117	CD47 Interleukin Related	Cancer
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .

HY-P99631

Garadacimab 1 Publications Verification CSL312	Factor Xa	Cardiovascular Disease
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .

HY-P99044

Sabatolimab 1 Publications Verification MBG453	Tim3	Inflammation/Immunology
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .

HY-P99457

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology Cancer
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .

HY-P99357

Crotedumab REGN1193; Anti-GCGR Reference antibody (crotedumab)	GCGR	Metabolic Disease
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes .

HY-P990070

Zigakibart BION-1301	TNF Receptor
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonal antibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .

HY-P99758

Nofazinlimab CS1003	PD-1/PD-L1	Cancer
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma .

HY-P990952

Zaltenibart OMS906	Ser/Thr Protease Complement System	Metabolic Disease Inflammation/Immunology
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .

HY-P99053

Tralokinumab 2 Publications Verification CAT354	Interleukin Related Apoptosis Caspase Cadherin	Inflammation/Immunology
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .

HY-P99203

Cemiplimab REGN-2810; SAR-439684	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

HY-P99305

Metelimumab 3 Publications Verification CAT-192; Anti-TGFB1 Recombinant antibody	TGF-β Receptor	Inflammation/Immunology
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .

HY-P99363

Feladilimab Anti-ICOS/CD278 Reference antibody (feladilimab); GSK3359609	Transmembrane Glycoprotein	Cancer
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS/CD278 agonist monoclonal antibody. Feladilimab can be used for the research of cancer .

HY-P99026

Lemzoparlimab 1 Publications Verification TJ011133; TJC4	CD47	Cancer
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .

HY-P990319

ALT-100 (Human IgG4)	NAMPT	Inflammation/Immunology
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P99744

Modakafusp alfa TAK-573	CD38	Inflammation/Immunology Cancer
Modakafusp alfa (TAK-573) is a humanized, *anti-CD38* *IgG4* monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .

HY-P99195

Fasinumab REGN-475; SAR-164877	Trk Receptor	Inflammation/Immunology
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .

HY-P99906

Sirexatamab DKN-01; LY-2812176	β-catenin	Cancer
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .

HY-P99263

Inclacumab 1 Publications Verification Anti-Human selectin P Recombinant antibody	P-selectin	Cardiovascular Disease
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a K_d value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC₅₀ value of 1.9 μg/mL and strongly inhibits cell adhesion .

HY-P99870

Eblasakimab ASLAN004; CSL-334; MK-6105	Interleukin Related	Others
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P990737

Eltrekibart LY-3041658	CXCR	Inflammation/Immunology
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990773

Venanprubart LY-3361237	CD28	Inflammation/Immunology
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990726

Abiprubart KPL-404	TNF Receptor	Inflammation/Immunology
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P991301

IMP-761	LAG-3	Cancer
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P9972

Spartalizumab PDR001	PD-1/PD-L1 IFNAR	Cancer
Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a K_d of 0.83 nM for human PD-1 and a K_d of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .

HY-P99724

Manfidokimab AK120	Interleukin Related	Inflammation/Immunology
Manfidokimab (AK120) is an anti-interleukin 4 receptor alpha (IL-4Rα) IgG4 monoclonal antibody .

HY-P990555

BI-765063 OSE-172	CD47	Inflammation/Immunology
BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

HY-P991183

SAR-442257	CD28 CD38 CD3	Cancer
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .

HY-P99028

Ibalizumab TMB-355; TNX-355	HIV	Infection
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .

HY-P990751

Nelmastobart HSTC-810	Transmembrane Glycoprotein	Inflammation/Immunology
Nelmastobart is an anti-BTN1A1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P99027

Ieramilimab LAG525; IMP701; Hu5A8	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .

HY-P991038

Zadoprubart	CD28	Inflammation/Immunology
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991705

Nebaprubart JJP-1212	Fc Receptor (FcR)	Inflammation/Immunology
Nebaprubart (JJP-1212) is a humanized IgG4κ antibody against FCAR/CD89, and its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P991698

Liscastobart BAT-1308	PD-1/PD-L1	Cancer
Liscastobart is a humanized IgG4κ antibody targeting PDCD1/PD-1/CD279. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P990913

Dalmitamig bsAb7075; REGN-7075; Marlotamig	EGFR	Inflammation/Immunology
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991670

Abdakibart AVTX-009	Interleukin Related	Inflammation/Immunology
Abdakibart is a humanized IgG4 monoclonal antibody inhibitor targeting IL-1β. Abdakibart can be used for inflammatory disease like type 2 diabetes research .

HY-P991067

Vensobafusp alfa KP-104	Complement System	Inflammation/Immunology
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .

HY-P99695

Lerdelimumab CAT-152	TGF-beta/Smad	Neurological Disease
Lerdelimumab (CAT-152) is an IgG4 human *anti-TGF-β2* recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .

HY-P990750

Negalstobart IBI-110	LAG-3	Inflammation/Immunology
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990691

Vilamakitug XB-2001	Interleukin Related	Inflammation/Immunology
Vilamakitug (XB-2001) is an anti-IL-1α human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P991686

Gamgertamig	TNF Receptor CD3	Inflammation/Immunology Cancer
Gamgertamig is a humanized IgG4 bispecific antibody targeting TNFRSF17 & CD3E .

HY-P991065

Ichorcumab JNJ-375; JNJ-64179375; JNJ-9375	Thrombin	Cardiovascular Disease
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003) .

Host:	Rabbit (2)
Reactivity:	Human (2)
Application:	IHC-P (2) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1) Recombinant (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83582

	*Human IgG4* Antibody (YA3327)** IgG4; Ig gamma 4 chain C region	WB, IHC-P	Human
	Human IgG4 Antibody (YA3327) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Human IgG4.

HY-P83582A

	*Human IgG4* Antibody (YA3327)(PBS only)** IgG4; Ig gamma 4 chain C region	WB, IHC-P	Human
	Human IgG4 Antibody (YA3327) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Human IgG4.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: